Menu
4C Biomed’s technology leverages a uniquely sensitive, immunological-based screening platform, which not only identifies novel immuno-oncology targets but also promises to accelerate the journey from discovery to clinical application.
Our unique and robust technology combines patient-derived tumor cultures or fresh tumor digests with autologous immune cells (TILs or PBMCs, respectively), providing accurate immune context. High-throughput screening methods, integrated with clinical data annotations, allows a bottom-up functional view. This workflow assists in prioritizing functionally-identified targets followed by stringent literature review, ensuring clinically relevant discoveries.
HVEM, also known as TNFRSF14 or CD270, is a unique cell surface receptor that can bind to TNF superfamily molecules as well as immunoglobulin molecules. Abnormal expression of HVEM has been reported in various cancer types, making it a promising target for immunotherapy. When HVEM binds to BTLA, it produces an inhibitory signal within the immune cell, which reduces T cell proliferation and increases cancer survival. Blocking the HVEM-BTLA interaction will alleviate the inhibitory effect on BTLA signaling. We have developed anti-4CB1, a novel fully human therapeutic anti-HVEM monoclonal antibody which is capable of blocking HVEM-BTLA interaction, inhibit downstream BTLA signaling and enhance the cytotoxicity of lymphocytes towards tumor cells.
Our lead has been rigorously tested In-Vitro, Ex-Vivo and In-Vivo, both as monotherapy and in combination with the gold standard, anti-PD-1 and has repeatedly achieved remarkable results. Anti-4CB1 is undergoing IND-enabling studies and is planned to enter clinical Phase 1 in 2025.
Our unique platform has a proven record of identifying IO targets: Over 20% of the immune checkpoints we have discovered have reached the stage of clinical trials by pharma companies
Multiple patents filed, including for anti-4CB1, fully human first in class therapeutic monoclonal antibody
Awarded the IIA Grant for innovative research
Anti-4CB1 cell line and manufacturing process development completed
Our lead antibody, anti-4CB1, has promising safety and efficacy data